14 articles
The Delhi High Court, in a significant ruling dated March 24th, 2024, rejected the interim injunction application of F Hoffmann-La Roche AG (“Roche”) against Natco Pharma Ltd. (“Natco”),…
The Delhi High Court upheld the validity of Novartis’s Ceritinib patent against Natco’s challenge, addressing divisional application issues and allegations of suppression. The injunction against Natco remains in…
The Delhi High Court Division Bench set aside an injunction against Natco Pharma in the Novartis Eltrombopag patent dispute. The judgment provides key guidance on patent validity challenges…
The Delhi High Court’s decision in Kudos Pharma v. Natco Pharma reviews crucial aspects of patent law, including credible challenge and the distinction between patent coverage and disclosure.…
The Delhi High Court analysed whether Natco Pharma’s process infringed FMC Corporation’s patented method for producing chlorantraniliprole. The court, relying on expert opinions, found key differences in process…
The Delhi High Court has provided clear procedural guidance for patent opposition proceedings, focusing on transparency and fair opportunity for all parties. The judgment underscores the importance of…
This week’s patent news highlights the Supreme Court’s extension of limitation periods and Natco Pharma’s new license for Molnupiravir. Updates also include important patent litigation developments in India…
This article examines recent patent litigation before the Delhi High Court, highlighting cases involving Novartis and Sulphur Mills in 2021. It discusses key judicial findings on patent validity,…
Natco Pharma has withdrawn its compulsory license application for Baricitinib following an agreement with Eli Lilly. The Indian Patent Office has extended procedural deadlines, and other significant updates…
This bulletin highlights Prime Minister Modi’s emphasis on innovation and patenting, the upcoming GIPC in New Delhi, and crucial legal updates such as Taiho Pharmaceutical’s lawsuit against Natco…